RCP Therapeutics Ltd acquires the IP and assets of Telemolecular Corporation
New operational headquarters situated in London, UK
RCP Therapeutics, a biopharmaceuticals company specialising in converging nanotechnology and regenerative medical markets, announced that it has exclusively licensed technologies from Telemolecular Corporation (USA). The Company’s portfolio of intellectual property is strategically focused on the regenerative, preventative and curative elements of age related disease states.
RCP Therapeutics has identified a series of product candidates and has pilot launched its lead product candidate, Bimene, a novel cosmeceutical topical product, utilising its nano particle delivery platform acquired via licenses from universities and US based research institutions.
New management, appointed to run Telomolecular Corporation in May 2008, set in motion a business strategy culminating in the formation of RCP Therapeutics. Operationally, the Company will retain its research laboratory in Sacramento, securing the facilities status as RCP Therapeutics’ primary research and development site. Furthermore, the Company’s plans to expand the Californian operation and increase the number of scientists and staff employed at the site. Commercialisation of RCP Therapeutics’ cosmeceutical products in the US will be co-ordinated from the same location.
Other news from the department business & finance
These products might interest you
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
